The utilization of liquid fuel in a molten salt reactor (MSR) provides greater access to advanced medical isotopes that have been proven to be effective at diagnosing and treating certain diseases such as cancer.  With continued advancement in MSR technologies, we believe we will eventually be able to harvest alpha particles that can be used in Targeted Alpha Therapy (TAT).  This targeted radiation therapy selectively targets cancer cells while minimizing damage to the surrounding healthy cells. 

The images below show the successful results of using TAT to treat prostate cancer that had spread through the patient’s body.

Bruchersteifer, F., Kellerbauer, A., Malmbeck, R. & Morgenstern, A.  (2019).  Targeted alpha therapy with busmuth-213 and actinium-225: Meeting future demand.  Journal of Labelled Compounds and Radiopharmaceuticals.